0PNT Acacia Pharma Group Plc

 
TIDMACPH 
 
 
   THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION. 
 
 
 
 
Publication in application of Article 15 of the Law of 2 May 2007 
                      (the Transparency Law) 
----------------------------------------------------------------- 
 
 
   Acacia Pharma Group plc 
 
   Cambridge, UK and Indianapolis, US -- 11 March 2021, 18:00 CET. As 
previously announced(1) , Acacia Pharma Group plc launched a capital 
increase in cash within the authorized capital. The gross amount of this 
capital increase amounted to EUR 27 million via an issue of 10,000,000 
new shares at an issue price of EUR 2.70 per share. The capital increase 
was achieved through an exempt accelerated private placement with 
international qualified and/or institutional investors with the 
composition of an order book (an accelerated bookbuilding). Additionally, 
116,000 shares were issued in January and February 2021(2) to satisfy 
the exercise of options granted under the Company's Enterprise 
Management Incentive Share Option Plan at an exercise price of GBP 2.00 
per share. 
 
 
 
 
Total amount of share capital on 28 
 February 2021                          GBP 1,994,279.02 
-------------------------------------  ------------------ 
Total amount of share premium on 28 
 February 2021                         GBP 142,087,474.57 
-------------------------------------  ------------------ 
Total number of shares with voting 
 rights on 28 February 2021                    99,713,951 
-------------------------------------  ------------------ 
Total number of voting rights on 28 
 February 2021 (denominator)                   99,713,951 
-------------------------------------  ------------------ 
Total number of outstanding warrants              201,330 
-------------------------------------  ------------------ 
Total number of outstanding employee 
 share options and restricted stock 
 units (RSUs)(3)                                5,274,961 
-------------------------------------  ------------------ 
 
 
   1. Press release of 19 February 2021 -- Results of Placing -- EUR 27 million 
      Raised to Invest Further in US Launch and Commercialization Activities 
 
   2. Press releases of: 
 
          1. 20 Jan 2021 -- Issue of Equity on Exercise of Options / Vesting of 
             Performance Share Awards 
 
          2. 04 Feb 2021-- Issue of Equity on Exercise of Options / Vesting of 
             Performance Share Awards 
 
          3. 12 Feb 2021 -- Issue of Equity on Exercise of Options / Vesting of 
             Performance Share Awards 
 
          4. 26 Feb 2021 -- Issue of Equity on Exercise of Options / Vesting of 
             Performance Share Awards 
 
   3. Of the 5,274,961 options and RSUs currently outstanding, 1,592,518 will 
      be satisfied through the transfer of shares already issued and admitted 
      to trading and held within the Acacia Pharma Group plc Employee Benefit 
      Trust. 
 
 
   Contacts 
 
 
 
 
Acacia Pharma Group plc             International Media 
 Mike Bolinder, CEO                  Mark Swallow, Frazer Hall, David 
 Gary Gemignani, CFO                 Dible 
 +44 1223 919760 / +1 317 505 1280   Citigate Dewe Rogerson 
 IR@acaciapharma.com                 +44 20 7638 9571 
                                     acaciapharma@citigatedewerogerson.com 
----------------------------------  -------------------------------------- 
US Investors                        Media in Belgium and the Netherlands 
 LifeSci Advisors                    Chris Van Raemdonck 
 Irina Koffler                       +32 499 58 55 31 
 +1 917-734-7387                     chrisvanraemdonck@telenet.be 
 ikoffler@lifesciadvisors.com 
----------------------------------  -------------------------------------- 
 
   Acacia Pharma Group plc 
 
   The Officers' Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United 
Kingdom 
 
   Company number 9759376 
 
   About Acacia Pharma 
 
   Acacia Pharma is a hospital pharmaceutical company focused on the 
development and commercialization of new products aimed at improving the 
care of patients undergoing significant treatments such as surgery, 
other invasive procedures, or cancer chemotherapy. The Company has 
identified important and commercially attractive unmet needs in these 
areas that its product portfolio aims to address. 
 
   Acacia Pharma's first product, BARHEMSYS(R) (amisulpride injection) is 
marketed in the US for the management of postoperative nausea & vomiting 
(PONV). 
 
   BYFAVO(TM) (remimazolam) for injection, a very rapid onset/offset IV 
benzodiazepine sedative is approved and launched in the US for use 
during invasive medical procedures in adults lasting 30 minutes or less, 
such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion 
UK Limited for the US market. 
 
   APD403 (intravenous and oral amisulpride), a selective dopamine 
antagonist for chemotherapy induced nausea & vomiting (CINV) has 
successfully completed one proof-of-concept and one Phase 2 dose-ranging 
study in patients receiving highly emetogenic chemotherapy. 
 
   Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D 
operations are centered in Cambridge, UK. The Company is listed on the 
Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker 
symbol ACPH. 
 
   www.acaciapharma.com 
 
 
 
 

(END) Dow Jones Newswires

March 11, 2021 12:00 ET (17:00 GMT)

Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Mar 2024 to Apr 2024

Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Apr 2023 to Apr 2024